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PCN147 FIELD TESTING OF A MULTICRITERIA DECISION ANALYSES (MCDA) FRAMEWORK FOR COVERAGE OF A DIAGNOSTIC TEST FOR CERVICAL CANCER IN SOUTH AFRICA
Miot J 1 , Wagner M 2 , Khoury H 2 , Anderson AN 3 , Rindress D 2 , Goetghebeur MM 2 1 University of Pretoria, Pretoria, Gauteng, South Africa, 2 BioMedCom Consultants Inc, Montreal, QC, Canada, 3 Discovery Health, Sandton, Johannesburg, South Africa OBJECTIVES: To field test the EVIDEM framework applying multicriteria decision analyses (MCDA) to support health care decisionmaking, with a private health care payer in South Africa. METHODS: Liquid based cytology (LBC) for cervical cancer screening was selected as a intervention requiring a coverage decision which would benefit from an MCDA approach. The matrix included 15 components of decision in four domains (quality of evidence, disease, intervention and economics). A synthesized health technology assessment report tailored to investigate each component was prepared. The decisionmaking committee estimated the MCDA value of LBC by assigning weights and scores for each matrix component. A survey instrument was administered to explore validity and outcomes of approach. RESULTS: Value of LBC was estimated at 58% of maximum value on the MCDA scale. Main contributors to value were relevance and validity of evidence, disease severity and risk reduction. Minor clinical improvement and significant economic impact contributed little to value. On average, 86% of committee members indicated that the same 12 components the MCDA matrix should always be considered. Non quantifiable components of decision were also identified and discussed. A majority of participants reported that the framework would improve: understanding of intervention; access to data on quality of evidence; consideration of key elements of decision; transparency of the decision; and understandability of decision by stakeholders. CONCLUSIONS: The EVIDEM framework provides a transparent record of how evidence and values are assessed during the decisionmaking process. Further testing and validation is needed to advance MCDA approaches in health care decisionmaking.
PCN148 ADDRESSING DECISIONS ABOUT CLINICAL GUIDANCE AND ITS ACTIVE IMPLEMENTATION: SEQUENTIAL OR INTEGRAL ANALYSIS? AN APPLICATION IN METASTATIC HORMONE-REFRACTORY PROSTATE CANCER
Hoomans T 1 , Severens JL 2 , Ament AJHA 1 , Fenwick E 3 1 Maastricht University, Maastricht, The Netherlands, 2 University Hospital Maastricht, Maastricht, The Netherlands, 3 University of Glasgow, Glasgow, UK BACKGROUND: In allocating resources to improve patient care, two decisions must be addressed: 1) whether to issue guidance on the use of a health technology considering its cost-effectiveness, and 2) whether to invest in the active implementation of such guidance (e.g. via education, incentives or regulation), as its clinical use does not necessarily follow. Since these two decisions are related, resource allocation can be based on either sequential (1-by-1) or integral analysis. OBJECTIVES: To identify the preferred approach to the analysis for addressing decisions about issuing and actively implementing clinical guidance. APPLICATION: The application relates to the allocation of resources to metastatic hormone-refractory prostate cancer (mHRPC) in the UK. METHODS: An integrated Bayesian approach to decision modeling and evidence synthesis is adopted. Evidence on the costs and QALYs of all plausible treatment regimens is combined with estimates of treatment usage and population size. Implementation costs and effects are assumed to vary between treatment options. Both sequential and integral analyses of resource allocation are performed. RESULTS: (preliminary): For cost-effectiveness thresholds £25,000-£32,000 per QALY, decisions about how best to improve care for mHRPC patients differ between the alternative analytic approaches. Based on sequential analysis, Mitoxantrone Prednisone is deemed costeffective, without actively implementing this guidance. An integral analysis reveals that active implementation of Docetaxel Prednisone (3 weekly) is the cost-effective option, yielding an additional 0.05 QALY per patient. By combining uncertain evidence on treatment regimens, their usage and active implementation, allowance is made for all uncertainty associated with resource allocation in mHRPC. CONCLUSIONS: For the analysis of the related decisions about 1) issuing, and 2) actively implementing clinical guidance, an integral approach is preferred over a sequential one. As the application in mHRPC demonstrates, integral analysis provides better options for improving patient management, more comprehensive insight in decision uncertainty and, consequently, an efficient allocation of resources.
PCN149 COST ANALYSIS OF 10-YEARS FOLLOW-UP OF CHEMOTHERAPY REGIMENS WITHIN THE SLOVAK REPUBLIC
Tesar T, Foltan V, Binder R Comenius University, Bratislava, Slovak Republic OBJECTIVES: The aim of this study was to collect comparable and reliable data on the chemotherapy regimens in Slovakia during the period 1999-2008. The special interest was paid to the trend of antineoplastic agents, endocrine therapy, immunostimulants and immunosuppressants usages. METHODS: Data of wholesalers (following ATC/DDD), who are legally obliged provide this information to the Slovak Institute for Drug Control, was used for the analysis. The results were expressed in finance units (a) and defined daily doses per 1000 inhabitants per day (DID).
RESULTS:
The collected data showed a dramatic increase in chemotherapy from 1999 to 2008 in term of DID-in 1999 DID-in (17.55), in 2003 DID-in (30.33) and in 2008 . We can see a significant increase in consumption of antineoplastic agents (DID)-in 1999 (DID)-in (11.75), in 2003 (DID)-in (18.06) and in 2008 ) and a noticeable increase in endocrine therapy-in 1999 (1.71), in 2003 (1.49) and in 2008 (2.48) . Unstable consumption of immunostimulants-in 1999 (3.76), in 2003 (10.15) and in 2008 (5.06) , and a moderate increase in consumption of immunosuppressants-in 1999 (0.31), in 2003 (0.62) and in 2008 (1.29) can be seen from this analysis. Results showed a dramatic increase in consumptions from the financial perspective-antineoplastic agents in 1999 (a5,440,000), in 2003 (a16,599,000) and in 2008 (a97,915,000), endocrine therapy in 1999 (a3,292,000), in 2003 (a6,779,000) and in 2008 (a14,186,000), immunostimulants in 1999 (a5,248,000), in 2003 (a15,538,000) and in 2008 (a24,178,000), immunosuppressive agents in 1999 (a3,867,000), in 2003 (a8,109,000) and in 2008 (a28,288,000) . CONCLUSIONS: Inseparable components of the Slovak drug policy must be viewed realistically with regard to chemotherapy regimens, which cause huge financial expenditures within the Slovak health care budget.
PCN150 THE RELATIONSHIP BETWEEN DRUG UTILIZATION AND OUT OF POCKET EXPENSES FOR ORAL ANTINEOPLASTICS COMPARED TO A MARKET BASKET OF COMMONLY USED DRUGS
Sepulveda B, Doyle JJ, White C Quintiles Consulting, Hawthorne, NY, USA OBJECTIVES: To evaluate the relationship between the average out of pocket cost (OPC) paid and the total prescription volume (TRx) for oral antineoplastics compared to a market basket of commonly utilized oral drugs. Is drug utilization more sensitive to OPC changes when there is greater competition and/or when the ailments treated by those drugs are less acute? We hypothesized an inverse proportional relationship between OPC and TRx. METHODS: We obtained monthly OPC data and TRx data from SDI's VONA and VOPA databases from January 2007-April 2009. We
